Table 3.

Baseline serum insulin, glucose, molar ratio of insulin to glucose and HOMA-IR stratified by lung cancer stage

	Low Stage (I-II)		High Stage (III-IV)
	# Cases/# Non-Cases	HR (95% CI)	# Cases/#Non-Cases	HR (95% CI)	p for heterogeneity by stage
Insulin, μU/mL
≤2.70	26/96	1.00 (ref)	44/96	1.00 (ref)	0.70
>2.70 to ≤4.10	16/97	0.89 (0.40 2.00)	35/97	1.08 (0.60, 1.92)
>4.10 to ≤6.10	8/100	0.56 (0.22, 1.45)	25/100	0.97 (0.51, 1.87)
>6.10	20/89	2.85(1.14, 7.15)	34/89	1.94 (0.93, 4.06)
p-trend		0.01		0.23
Glucose, mg/dL
≤92	26/96	1.00 (ref)	45/96	1.00 (ref)	0.22
>92 to ≤98	18/93	0.63 (0.29, 1.37)	37/93	0.85 (0.49, 1.49)
>98 to ≤107	15/99	0.59 (0.26, 1.37)	33/99	0.96 (0.52, 1.76)
>107	11/94	0.54 (0.22, 1.33)	23/94	0.76 (0.39, 1.48)
p-trend		0.48		0.84
Molar ratio of insulin to glucose
≤0.03	24/94	1.00 (ref)	40/94	1.00 (ref)	0.26
>0.03 to ≤0.04	15/97	0.66 (0.30, 1.47)	37/97	1.10 (0.62, 1.96)
>0.04 to ≤0.06	16/98	0.98 (0.44, 2.20)	30/98	1.07 (0.58, 1.98)
>0.06	15/93	1.76 (0.69, 4.46)	31/93	1.71 (0.84, 3.46)
p-trend		0.24		0.46
HOMA-IR
≤0.67	26/95	1.00 (ref)	43/95	1.00 (ref)	0.89
>0.67 to ≤1.02	18/97	0.87 (0.41, 1.85)	36/97	1.00 (0.56, 1.80)
>1.02 to ≤1.53	7/97	0.45 (0.16, 1.24)	25/97	1.04 (0.54, 2.03)
>1.53	19/93	2.25 (0.89, 5.69)	34/93	1.78 (0.87, 3.61)
p-trend		0.02		0.34

^*Model adjusted for age, body mass index, family history and pack years of smoking